Particularly, the anti-PD(L)1 monoclonal antibody (mAb) durvalumab, in combination with the anti-NKG2A mAb monalizumab, has shown interesting response rates and progression-free survival when administered to patients with unresectable, stage III NSCLC in the phase 2 COAST trial (NCT03822351). Here, KLRC1 is linked to non-small cell lung carcinoma.